专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2023038624A1 ENZYMATIC DEGRADATION OF MYCOTOXINS DURING FERMENTATION AND POST-FERMENTATION 审中-公开
公开(公告)号：WO2023038624A1
公开(公告)日：2023-03-16
申请号：PCT/US2021/049589
申请日：2021-09-09
申请人： POET RESEARCH, INC.
发明人： MANNING, Andrew J. , BLY, Steven T.
IPC分类号： A23K10/14 , A23K10/30 , A23K10/38 , A23K20/189 , A23L5/20 , A23L7/104 , A61P31/10 , A61P39/00 , C12N9/02 , C12N15/52
摘要： Methods, compositions, and systems for steeping, propagation and fermentation, particularly large-scale operations for production of starch and ethanol and fermentation product streams are provided. Addition of mycotoxin mitigating enzymes or microorganisms expressing mycotoxin mitigating enzymes to steeping, propagation, and/or fermentation tanks, and/or to post-fermentation product streams, mitigates mycotoxin levels in fermentation co-products obtained from mycotoxin contaminated feedstocks.

2. 发明申请

WO2022087243A1 ANTI-FGFR2 ANTIBODIES AND METHODS OF USE THEREOF 审中-公开
公开(公告)号：WO2022087243A1
公开(公告)日：2022-04-28
申请号：PCT/US2021/056018
申请日：2021-10-21
申请人： REGENERON PHARMACEUTICALS, INC.
发明人： DALY, Christopher , DELFINO, Frank , HAN, Amy , NITTOLI, Thomas , ZHANG, Li
IPC分类号： C07K16/28 , C07K16/30 , A61P35/00 , A61K47/68
摘要： Provided herein are monoclonal antibodies, and antigen-binding fragments thereof, that bind fibroblast growth factor receptor 2 (FGFR2), and methods of use thereof and methods of use thereof. Also included are antibody-drug conjugates (ADCs) comprising the anti-FGFR2 antibodies or antigen-binding fragments thereof linked to a cytotoxic agent, radionuclide, or other moiety, as well as methods of treatment using the same.

3. 发明申请

WO2022032011A1 ENDOGENOUS LIPASE FOR METAL REDUCTION IN DISTILLERS CORN OIL 审中-公开
公开(公告)号：WO2022032011A1
公开(公告)日：2022-02-10
申请号：PCT/US2021/044812
申请日：2021-08-05
申请人： POET RESEARCH, INC.
发明人： MANNING, Andrew J. , MCCURDY, Alex T. , BLY, Steven T.
IPC分类号： C12P7/64 , C12P7/06 , C11B1/02 , C11B13/00 , C11C3/00 , C12N9/20 , C12P39/00 , C11B1/025 , C11C3/003 , C12P2203/00 , C12P7/14 , C12P7/6436 , C12Y301/01003
摘要： Provided herein are compositions, methods, systems associated with propagation and fermentation, and co-products of biochemical production processes, for example, a DCO co-product resulting from converting oil containing grains into bio chemicals via fermentation in the presence of endogenous esterase. The DCO resulting from the processes exhibits lower metal ion content relative to a DCO obtained in the absence of endogenous fermentation with an esterase such as a lipase. The DCO is useful as a feedstock for the production of renewable diesel.

4. 发明申请

WO2021086899A1 ANTI-HEMAGGLUTININ ANTIBODIES AND METHODS OF USE THEREOF 审中-公开
公开(公告)号：WO2021086899A1
公开(公告)日：2021-05-06
申请号：PCT/US2020/057635
申请日：2020-10-28
申请人： REGENERON PHARMACEUTICALS, INC.
发明人： BAUM, Alina , KYRATSOUS, Christos
IPC分类号： C07K16/10 , A61K39/42 , A61K39/395 , A61P31/16
摘要： Provided herein are monoclonal antibodies, or antigen-binding fragments thereof, that bind to the influenza B hemagglutinin (HA) protein, pharmaceutical compositions comprising the antibodies and methods of use. The antibodies are useful for inhibiting or neutralizing influenza B virus activity, thus providing a means of treating or preventing influenza infection in humans. Also provided is the use of one or more antibodies that bind to the influenza B HA for preventing viral attachment and/or entry into host cells. The antibodies may be used prophylactically or therapeutically and may be used alone or in combination with one or more other anti-viral agents or vaccines.

5. 发明申请

WO2020257681A1 USE OF BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3 IN COMBINATION WITH 4-1BB CO-STIMULATION 审中-公开
公开(公告)号：WO2020257681A1
公开(公告)日：2020-12-24
申请号：PCT/US2020/038786
申请日：2020-06-19
申请人： REGENERON PHARMACEUTICALS, INC.
发明人： KIRSHNER, Jessica R. , CRAWFORD, Alison , CHIU, Danica
IPC分类号： C07K16/28 , C07K16/30 , C07K16/46 , A61K39/00
摘要： Provided herein are methods of treating cancer using bispecific antigen-binding molecules that bind to prostate-specific membrane antigen (PSMA) and CD3. According to certain embodiments, the antibodies useful herein bind human PSMA with high affinity and bind CD3 to induce human T cell proliferation. According to certain embodiments, bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD3, and a second antigen-binding molecule that specifically binds human PSMA are particularly useful herein. In certain embodiments, the bispecific antigen-binding molecules in combination with an anti-4-1BB agonist are capable of inhibiting the growth of prostate tumors expressing PSMA. The bispecific antigen-binding molecules in combination with an anti-4-1BB agonist are useful for the treatment of diseases and disorders in which an upregulated or induced targeted immune response is desired and/or therapeutically beneficial, for example, in the treatment of various cancers.

6. 发明申请

WO2020154706A1 UTERINE ENDOMETRIAL FLUID FOR PREDICTION OF SUCCESS IN FERTILITY TREATMENT 审中-公开
公开(公告)号：WO2020154706A1
公开(公告)日：2020-07-30
申请号：PCT/US2020/015110
申请日：2020-01-24
申请人： FERTILITY LAB SCIENCES, LLC
发明人： KATZ-JAFFE, Mandy , SCHOOLCRAFT, William B.
IPC分类号： G01N33/68
摘要： Provided herein are methods, systems, and kits for improving success rates in assisted reproductive technologies such as in vitro fertilization, frozen embryo transfer, and intrauterine insemination. These methods, systems, and kits rely on levels of protein, metabolite, and microRNA markers determined herein to be linked to uterine toxicity and embryo implantation failure.

7. 发明申请

WO2019195796A1 A LEPTIN RECEPTOR AGONIST ANTIBODY FOR USE IN TREATING A METABOLIC DYSFUNCTION OR HYPOLEPTINEMIA 审中-公开
公开(公告)号：WO2019195796A1
公开(公告)日：2019-10-10
申请号：PCT/US2019/026173
申请日：2019-04-05
申请人： REGENERON PHARMACEUTICALS, INC.
发明人： GROMADA, Jesper , STEVIS, Panayiotis , ALTAREJOS, Judith , MURPHY, Andrew J.
IPC分类号： A61K39/395 , A61P3/00 , A61P3/04 , A61P3/10
摘要： Provided herein are therapeutic methods of treatment using agonist leptin receptor (LEPR) antibodies, antigen-binding fragments thereof, or compositions comprising the LEPR antibodies or antigen-binding fragments thereof. Such therapeutic methods include treatment for conditions related to metabolic dysfunction, including for example, lipodystrophy, adiposity or obesity, reducing body weight, non-alcoholic fatty liver disease, hyperphagia, hyperglycemia, insulin resistance, dyslipidemia, hepatic steatosis, and infertility.

8. 发明申请

WO2018089532A1 ANTIGEN-BINDING PROTEINS THAT ANTAGONIZE LEPTIN RECEPTOR 审中-公开
标题翻译：抗约束蛋白受体的抗原结合蛋白
公开(公告)号：WO2018089532A1
公开(公告)日：2018-05-17
申请号：PCT/US2017/060690
申请日：2017-11-08
申请人： REGENERON PHARMACEUTICALS, INC.
发明人： GROMADA, Jesper , STEVIS, Panayiotis , ALTAREJOS, Judith
IPC分类号： C07K16/28 , A61K39/395
摘要： The present invention provides antibodies and antigen-binding fragments of antibodies that bind to leptin receptor (LEPR), and methods of using the same. According to certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind LEPR and antagonize LEPR signaling. In certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind LEPR in the presence or absence of leptin. In other embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that exhibit partial agonism of LEPR signaling. The antibodies and antigen-binding fragments of the present invention are useful for the treatment of various conditions, including but not limited to congestive heart failure cachexia, pulmonary cachexia and cancer cachexia, autoimmune disorders such as inflammatory bowel disease, lupus erythematosus, multiple sclerosis, psoriasis, cardiovascular diseases, elevated blood pressure, neurodegenerative disorders, depression, cancer such as hepatocellular carcinoma, melanoma, breast cancer, and other diseases and disorders associated with or caused by elevated leptin signaling.
摘要翻译：本发明提供了与瘦素受体（LEPR）结合的抗体和抗体的抗原结合片段及其使用方法。根据某些实施方案，本发明包括结合LEPR并拮抗LEPR信号传导的抗体和抗体的抗原结合片段。在某些实施方案中，本发明包括在存在或不存在瘦素的情况下结合LEPR的抗体和抗体的抗原结合片段。在其他实施方案中，本发明包括显示LEPR信号传递的部分激动作用的抗体和抗体的抗原结合片段。本发明的抗体和抗原结合片段可用于治疗各种病症，包括但不限于充血性心力衰竭恶病质，肺恶病质和癌症恶病质，自身免疫病症如炎症性肠病，红斑狼疮，多发性硬化症，牛皮癣，心血管疾病，血压升高，神经退行性疾病，抑郁症，癌症如肝细胞癌，黑素瘤，乳腺癌以及与瘦素信号升高相关或由其引起的其他疾病和病症。

9. 发明申请

WO2017066204A1 ANTIGEN-BINDING PROTEINS THAT ACTIVATE THE LEPTIN RECEPTOR 审中-公开
标题翻译：激活LEPTIN受体的抗原结合蛋白
公开(公告)号：WO2017066204A1
公开(公告)日：2017-04-20
申请号：PCT/US2016/056465
申请日：2016-10-11
申请人： REGENERON PHARMACEUTICALS, INC.
发明人： GROMADA, Jesper , STEVIS, Panayiotis , ALTAREJOS, Judith
IPC分类号： C07K16/28 , A61P3/00 , A61P3/10 , A61P25/28 , A61K39/395
CPC分类号： C07K16/2869 , A61K39/395 , A61K2039/505 , C07K2317/21 , C07K2317/33 , C07K2317/34 , C07K2317/565 , C07K2317/75 , C07K2317/92
摘要： The present invention provides antibodies and antigen-binding fragments of antibodies that bind to leptin receptor (LEPR), and methods of using the same. According to certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind LEPR and activate LEPR signaling. In other embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind to LEPR and enhance sensitization of LEPR to an antigen. In certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind LEPR in the presence and absence of leptin. In certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that induce signaling in cells expressing LEPR mutants that otherwise exhibit defective or impaired signaling in the presence of leptin. The antibodies and antigen-binding fragments of the present invention are useful for the treatment of lipodystrophies and other diseases and disorders associated with or caused by leptin deficiency or leptin resistance.
摘要翻译：本发明提供了与瘦素受体（LEPR）结合的抗体和抗体的抗原结合片段及其使用方法。根据某些实施方案，本发明包括结合LEPR并激活LEPR信号传导的抗体和抗体的抗原结合片段。在其他实施方案中，本发明包括结合LEPR并增强LEPR对抗原的敏化的抗体和抗体的抗原结合片段。在某些实施方案中，本发明包括在存在和不存在瘦素的情况下结合LEPR的抗体和抗体的抗原结合片段。在某些实施方案中，本发明包括在表达LEPR突变体的细胞中诱导信号传导的抗体和抗体的抗原结合片段，所述LEPR突变体否则在存在瘦素的情况下表现出缺陷或受损的信号传导。本发明的抗体和抗原结合片段可用于治疗与瘦素缺乏或瘦素抗性相关或由瘦素缺乏或瘦素抗性引起的脂肪营养不良和其他疾病和病症。

10. 发明申请

WO2022178382A1 METHOD FOR DIAGNOSING AND TREATING PARTIAL LIPODYSTROPHY 审中-公开
公开(公告)号：WO2022178382A1
公开(公告)日：2022-08-25
申请号：PCT/US2022/017222
申请日：2022-02-22
申请人： REGENERON PHARMACEUTICALS, INC.
发明人： ZHENG, Wenjun , HARRIS, Charles , MUSSER, Bret
IPC分类号： A61B5/00
摘要： The present invention provides highly specific and selective methods for diagnosing partial lipodystrophy (e.g., familial partial lipodystrophy) in a subject. Methods for treating partial lipodystrophy are also provided.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式